Evolus stock just ripped almost 20% higher to US$7.41, and the move is all about one thing. The market is latching onto a margin and profitability turn that feels very different from the company investors watched over the past year.

Q2 revenue of US$84.1m, helped by aesthetics demand across toxins and fillers, arrived alongside a third straight quarter of positive adjusted earnings before interest, taxes, depreciation and amortization. That shift in earnings quality is what traders are watching. The question now is whether this new profitability rhythm justifies the sudden re rating or stretches the enthusiasm too far.

Love the fresh profitability at Evolus but want stocks where that margin profile already pairs with stronger balance sheet support and cash generation? Check out our hand picked list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$84.1m vs. US$69.4m (up about 21%)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$8.1m vs. loss of US$17.1m (loss narrowed by about 53%)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.12 per share vs. loss of US$0.27 per share (loss per share narrowed by about 54%)
• Adjusted EBITDA, Q2 2026 vs. Q2 2025: positive US$4.7m compared with a deeper adjusted EBITDA loss one year ago, marking a third straight quarter of positive adjusted EBITDA

Prefer clean, visual charts instead of scrolling through more earnings tables and raw numbers? Get a full picture of Evolus with an easy to read breakdown of its valuation in the company report for Evolus.

Evolus bull case leans on real operating traction

Bulls argue Evolus is shifting from a single product story to a broader aesthetics platform that can support sustained profitability. The quarter gives that view some backing. Revenue of US$84.1m with Jeuveau and the HA filler portfolio both contributing, plus a third straight period of positive adjusted EBITDA of US$4.7m, shows the margin work is not just a one off. Adjusted gross margin of 69% received a 120 bp lift from a tariff refund, yet even excluding that help, the margin range sits close to the 2026 guide of 67.0% to 67.5%. Management also raised the lower end of revenue guidance and narrowed operating expense guidance after the first half. That points to some cost discipline and execution on the portfolio and loyalty initiatives that sit at the heart of the bullish narrative.

Evolus bear case still flags concentration and execution risk

Bears focus on Evolus being heavily tied to Jeuveau, exposed to aesthetic cycle swings, and at risk of filler channel stuffing. The latest figures do not fully settle those worries. Toxin revenue of US$75.2m is still the clear majority of sales, so any slowdown in U.S. neurotoxin demand would matter. HA gel revenue of US$8.9m is growing from a small base and early strength could still reflect inventory build rather than durable procedure demand. The company remains loss making at the net income line with a US$8.1m loss, despite positive adjusted EBITDA, so the path to consistent bottom line profitability is not complete. International expansion, Profhilo and pipeline products have multi year timelines, which means they do not yet offset the concentration risk in the core U.S. toxin business.

After a 19.9% share price jump and with Evolus still reporting net losses, it is fair to ask whether product concentration, aesthetic demand swings and balance sheet pressure are just early warning signs. Review the independent risk analysis for Evolus which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Evolus looks interesting after its margin and adjusted EBITDA progress, register for free with Simply Wall St and add it to a Watchlist so you can watch how the share price tracks against fair value and decide on a potential entry point at your own pace. Once you are invested, keep your focus with the Portfolio Command Center that highlights only the most important changes to your holdings instead of every headline move. For a longer term view, use the Community to see how other investors are thinking about Evolus and similar stocks. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Evolus Stock?

Fresh stock ideas with real momentum can move from quiet accumulation to full breakout quickly. Screen under the radar for now, before the crowd catches up and act now.

• Hunt for resilient businesses that pair sturdy cash positions with consistent fundamentals by scanning the list of solid balance sheet and fundamentals stocks (49 results) while conditions still look favorable for patient capital.
• Spot early strength in companies riding the AI infrastructure build out and track the 56 AI infrastructure stocks before that story gets fully priced in by fast moving money.
• Position ahead of possible capital rotation into hard assets by reviewing the curated 31 elite gold producer stocks while sentiment around producers is still resetting and volume is building.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.